Studiencode: IOM-070337
| Institution: | iOMEDICO AG | ||
| Titel der NIS: | A non-interventional study of carfilzomib (Kyprolis) in combination with lenalidomide (Revlimid®) and dexamethasone or carfilzomib in combination with dexamethasone alone or carfilzomib in combination with daratumumab (Darzalex) and dexamethasone in patients with multiple myeloma who have received at least one prior therapy | ||
| Ziel der NIS: | The objective of this non-interventional study (NIS) is to evaluate patients’ adherence and persistence to carfilzomib therapy in combination with lenalidomide and dexamethasone or in combination with dexamethasone alone or in combination with dexamethasone and daratumumab in adult patients with multiple myeloma (MM) who have received at least one prior therapy in a real-life setting. |
||
| Ort der Durchführung: | nur Deutschland | NIS angefordert: | nein |
| Patientenanzahl insgesamt: | 359 | Anzahl Ärzte insgesamt: | 85 |
| Patientenanzahl in Deutschland: | 359 | Ärzte in Deutschland: | 85 |
| Anzeige am: | 16.02.2021 | Geplanter Beginn: | 21.09.2016 | Geplantes Ende: | 30.06.2025 |
| Arzneimittelbezeichnung | INN | Zulassungs-Nr. | ATC-Code | Substanzklasse |
|---|---|---|---|---|
| Kyprolis | Carfilzomib | L01XX45 | Antineoplatische Mittel | |
| Revlimid | Lenalidomid | L04Ax04 | Andere Immunsuppressiva | |
| Darzalex | Daratumumab | L01XC24 | Andere Antineoplastische Mittel |
| Art des Dokuments | |
|---|---|
| Beobachtungsplan, NIS 568 | pdf 1MB |
